Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-05-05T01:13:40.029Z Has data issue: false hasContentIssue false
  • English
  • Français

C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice

Published online by Cambridge University Press:  02 October 2011

A. Sicras-Mainar ,
J. Rejas-Gutiérrez ,
R. Navarro-Artieda  and
M. Blanca-Tamayo
A. Sicras-Mainar*
Affiliation:
Directorate of Planning, Badalona Serveis Assistencials, Badalona (Barcelona), Spain
J. Rejas-Gutiérrez
Affiliation:
Department of Health Outcomes Research, Corporate Affairs and Market Access Unit, Pfizer España, Alcobendas (Madrid), Spain
R. Navarro-Artieda
Affiliation:
Department of Medical Documentation, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain
M. Blanca-Tamayo
Affiliation:
Department of Psychiatry, Badalona Serveis Assistencials, Badalona (Barcelona), Spain
*
⁎Corresponding author. Tel.: +34 93 5072684. E-mail address:asicras@bsa.cat (A. Sicras-Mainar).
Get access

Abstract

Objective

Interest in cardiovascular diseases (CVD) in schizophrenia has grown recently due to documented incremental mortality. C-reactive protein (CRP) has been assessed as a marker in individuals with CVD and/or at high risk of developing it. However, its role in schizophrenia patients is unknown. The goal of this research was thus to explore the use of CRP as a marker of CVD risk in patients with schizophrenia.

Methods

A cross-sectional analysis of the Badalona Serveis Assistencials (BSA) administrative claims database was conducted including all subjects aged > 18 years with a diagnosis of schizophrenia spectrum disorder. CRP measurement, sociodemographics, medical history, 10-year CVD risk (Framingham function) and clinical chemistry data were extracted for analysis.

Results

Seven hundred and five patients (53.0% men, 48.2 [15.8] years, 78.7% on atypicals) met criteria for analysis. Mean 10-year CVD risk was high; 11.9 ± 5.7% and mean CRP levels were 2.6 ± 2.5 mg/L with 30.4% showing above-normative levels (> 3 mg/L). After adjusting for age, gender, smoking and presence of neoplasm or inflammatory diseases, CRP was linearly associated with 10-year CVD risk stratified by risk (low, moderate, high/very high): respectively, 2.3 (95% CI: 2.1–2.5), 3.1 (2.6–3.5) and 3.7 (3.2–4.1) mg/L; F = 13.5, P < 0.001. Patients with known CVD also showed higher CRP levels: 3.7 (2.9–4.5) vs. 2.5 (2.4–2.7) mg/L, P = 0.008; and higher probability of above-normal values; odds ratio = 4.71 (2.01–11.04), P < 0.001.

Conclusions

High CRP levels above normative were associated with both known CVD and high/very high 10-year risk of a CVD event in patients with schizophrenia, suggesting CRP could be a marker of CVD in this psychiatric disorder.

Keywords

C-reactive proteinSchizophrenia spectrum disordersCardiovascular riskFramingham functionReal world
Type
Original article
Information
European Psychiatry , Volume 28 , Issue 3 , March 2013 , pp. 161 - 167
Copyright
Copyright © European Psychiatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alegría, E.Cordero, A.Laclaustra, M.Grima, A.León, M.Casasnovas, J.A.et al., en representación de los investigadores del registro MESYAS. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev Esp Cardiol 2005;58:797–806.CrossRefGoogle Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington DC; 2000.Google Scholar
Bjerkeset, O.Romild, U.Smith, G.D.Hveem, K.The associations of high levels of C-reactive protein with depression and myocardial infarction in 9258 women and men from the HUNT population study. Psychol Med 2010;6:1–8.Google Scholar
Bobes, J.Arango, C.Aranda, P.Carmena, R.Garcia-Garcia, M.Rejas, J.Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90:162–173.CrossRefGoogle ScholarPubMed
Correll, C.U.Frederickson, A.M.Kane, J.M.Manu, P.Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotics drugs. J Clin Psychiatry 2006;67:575–583.CrossRefGoogle Scholar
Cunha, A.B.Andreazza, A.C.Gomes, F.A.Frey, B.N.da Silveira, L.E.Gonçalves, C.A., et al., Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008;258:300–304.CrossRefGoogle ScholarPubMed
Danesh, J.Wheeler, J.G.Hirschfield, G.M.Eda, S.Eiriksdottir, G.Rumley, A., et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–1397.doi: 10.1056/NEJMoa032804.CrossRefGoogle ScholarPubMed
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Holt, R.I.Möller, H.J.Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412–424.CrossRefGoogle Scholar
Dehghan, A.Kardys, I.De Maat, M.P.Uitterlinden, A.G.Sijbrands, E.J.Bootsma, A.H., et al., Genetic variation. C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872.CrossRefGoogle ScholarPubMed
Diaz, F.J.Pérez-Iglesias, R.Mata, I.Martínez-Garcia, O.Vázquez-Barquero, J.L.de Leon, J., et al., Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr Res 2010;121:207–212.CrossRefGoogle Scholar
Dickerson, F.Stallings, C.Origoni, A.Boronow, J.Yolken, R.C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007;93:261–265.CrossRefGoogle Scholar
Dinan, T.G.Inflammatory markers in depression. Curr Opin Psychiatry 2009;22:32–36.CrossRefGoogle ScholarPubMed
Douglas, K.M.Taylor, A.J.O’Malley, P.G.Relationship between depression and C-reactive protein in a screening population. Psychosom Med 2004;66:679–683.CrossRefGoogle Scholar
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.CrossRefGoogle Scholar
Fan, X.Pristach, C.Liu, E.Y.Freudenreich, O.Henderson, D.C.Goff, D.C.Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007;149:267–271.CrossRefGoogle Scholar
Genest, J.C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010;26(Suppl. A):41A–44A.CrossRefGoogle ScholarPubMed
Goldstein, B.I.Kemp, D.E.Soczynska, J.K.McIntyre, R.S.Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078–1090.CrossRefGoogle ScholarPubMed
Hagg, S.Lindblom, Y.Mjorndal, T.Adolfsson, R.High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93–98.Google ScholarPubMed
Keltner, N.L., Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006;42:204–207.CrossRefGoogle ScholarPubMed
Kones, R.The Jupiter study. CRP screening and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis 2009;3:309–315.CrossRefGoogle ScholarPubMed
Konnopka, A.Klingberg, S.Wittorf, A.König, H.H.The cost of schizophrenia in Germany: a systematic review of the literature. Psychiatr Prax 2009;36:211–218.CrossRefGoogle ScholarPubMed
Koro, C.E.Fedder, D.O.L’Italien, G.J.Weiss, S.S.Magder, L.S.Kreyenbuhl, J., et al., Assessment of independent effect of olanzapina and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243–245.CrossRefGoogle ScholarPubMed
Lamberts, H.Wood, M.Hofmans-Okkes, I.M., editors. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press; 1993.Google Scholar
Lawlor, D.A.Bedford, C.Taylor, M., et al.Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003;57:134–140.CrossRefGoogle ScholarPubMed
Malik, S.Wong, N.D.Franklin, S.S.Kamath, T.V.L’Italien, G.J.Pio, J.R., et al.Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245–1250.CrossRefGoogle ScholarPubMed
Marsik, C.Kazemi-Shirazi, L.Schickbauer, T.Winkler, S.Joukhadar, C.Wagner, O.F., et al.C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008;54:343–349.CrossRefGoogle Scholar
Martínez, M.A.Puig, J.G.Mora, M.Aragón, R.O’Dogherty, P.Antón, J.L., et al.Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study. Metabolism 2008;57:1232–1240.CrossRefGoogle ScholarPubMed
McEvoy, J.P.Meyer, J.M.Goff, D.C.Nasrallah, H.A.Davis, S.M.Sullivan, L., et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005;80:19–32.CrossRefGoogle ScholarPubMed
McGrath, J.Saha, S.Chant, D.Welham, J.Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76.CrossRefGoogle Scholar
Meyer, J.M.McEvoy, J.P.Davis, V.G.Goff, D.C.Nasrallah, H.A.Davis, S.M., et al.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009;66:1013–1022.CrossRefGoogle ScholarPubMed
Meyer, J.M.Stahl, S.M.The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4–14.CrossRefGoogle Scholar
Oud, M.J.Meyboom-de Jong, B.Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009;10:32.CrossRefGoogle ScholarPubMed
Pearson, T.A.Mensah, G.A.Alexander, R.W.Anderson, J.L.Cannon, R.O., 3rd.et al.Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.CrossRefGoogle ScholarPubMed
Pepys, M.B.Hirschfield, G.M.C-reactive protein: a critical update. J Clin Invest 2003;111:1805–1812.doi: 10.1172/JCI18921. PMID 12813013. PMC 161431.CrossRefGoogle ScholarPubMed
Pradhan, A.D.Manson, J.E.Rifai, N.Buring, J.E.Ridker, P.M.C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–334.doi: 10.1001/jama.286.3.327.CrossRefGoogle ScholarPubMed
Rejas, J.Bobes, J.Arango, C.Aranda, P.Carmena, R.Garcia-Garcia, M.Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 2008;99:23–28.CrossRefGoogle ScholarPubMed
Ridker, P.M.Buring, J.E.Cook, N.R.Rifai, N.C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391–397.CrossRefGoogle ScholarPubMed
Ridker, P.M.Hennekens, C.H.Buring, J.E.Rifai, N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.doi: 10.1056/NEJM200003233421202.CrossRefGoogle ScholarPubMed
Saha, S.Chant, D.McGrath, J.Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. Int J Methods Psychiatr Res 2008;17:55–61.CrossRefGoogle ScholarPubMed
Sattar, N.Gaw, A.Scherbakova, O.Ford, I.O’Reilly, D.S.Haffner, S.M., et al.Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–419.CrossRefGoogle ScholarPubMed
Scheepers-Hoeks, A.M.Wessels-Basten, S.J.Scherders, M.J.Bravenboer, B.Loonen, A.J.Kleppe, R.T., et al.Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview. Tijdschr Psychiatr 2008;50:645–654.Google ScholarPubMed
Schultze-Lutter, F.Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009;35:5–8.CrossRefGoogle ScholarPubMed
Strassnig, M.Brar, J.S.Ganguli, R.Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003;29:393–397.CrossRefGoogle ScholarPubMed
Timpson, N.J.Lawlor, D.A.Harbord, R.M.Gaunt, T.R.Day, I.N.Palmer, L.J., et al.C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 2005;366:1954–1959.CrossRefGoogle ScholarPubMed
Usher, K.Foster, K.Park, T.The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. J Psychiatr Ment Health Nurs 2006;13:730–734.CrossRefGoogle ScholarPubMed
Van den Buuse, M.Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010;36:246–270.CrossRefGoogle ScholarPubMed
Vuksan-Cusa, B.Sagud, M.Jakovljević, M.C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 2010;22:275–277.Google ScholarPubMed
Weis, S.Haybaeck, J.Dulay, J.R.Llenos, I.C.Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm 2008;115:761–771.CrossRefGoogle ScholarPubMed
Wilson, P.W.D’Agostino, R.B.Levy, D.Belanger, A.M.Silbershatz, H.Kannel, W.B.Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.CrossRefGoogle ScholarPubMed
Zacho, J.Tybjaerg-Hansen, A.Jensen, J.S.Grande, P.Sillesen, H.Nordestgaard, B.G.Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897–1908.doi: 10.1056/NEJMoa0707402.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.